These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Pitfalls in the assessment of prognostic factors. Metze K Lancet Oncol; 2011 Nov; 12(12):1095-6. PubMed ID: 22041541 [No Abstract] [Full Text] [Related]
13. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ Trials; 2015 Apr; 16():146. PubMed ID: 25873045 [TBL] [Abstract][Full Text] [Related]
15. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078 [TBL] [Abstract][Full Text] [Related]
17. Are all KRAS mutations created equal? Stinchcombe TE; Der CJ Lancet Oncol; 2011 Aug; 12(8):717-8. PubMed ID: 21782508 [No Abstract] [Full Text] [Related]
18. Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer. Ruco L; Scarpino S; Natoli G J Thorac Oncol; 2009 May; 4(5):670. PubMed ID: 19395916 [No Abstract] [Full Text] [Related]
19. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis. Yang SL; Ren QG; Wen L; Hu JL J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798 [TBL] [Abstract][Full Text] [Related]
20. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010 [No Abstract] [Full Text] [Related] [Next] [New Search]